nanoparticle albumin-bound paclitaxel; Nab-paclitaxel (Abraxane)
Jump to navigation
Jump to search
Indications
- for use in combination with gemcitabine for treatment of pancreatic cancer[3]
- metastatic breast cancer after failure (or contraindicaion) of anthracycline
- for use in combination with carboplatin for treatment of locally advanced or metastatic non-small cell lung carcinoma
Dosage
- injectable
Adverse effects
- see paclitaxel
Mechanism of action
- microtubule inhibitor
More general terms
References
- ↑ FDA News Release: Sept. 6, 2013 FDA approves Abraxane for late-stage pancreatic cancer. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm367442.htm
- ↑ Abraxane prescribing information http://www.abraxane.com/downloads/Abraxane_PrescribingInformation.pdf
- ↑ 3.0 3.1 Von Hoff DD et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med 2013 <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/24131140 <Internet> http://www.nejm.org/doi/full/10.1056/NEJMoa1304369